Cargando…

Administration of Glutaredoxin-1 Attenuates Liver Fibrosis Caused by Aging and Non-Alcoholic Steatohepatitis

Liver fibrosis is a sign of non-alcoholic fatty liver disease progression towards steatohepatitis (NASH) and cirrhosis and is accelerated by aging. Glutaredoxin-1 (Glrx) controls redox signaling by reversing protein S-glutathionylation, induced by oxidative stress, and its deletion causes fatty live...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsukahara, Yuko, Ferran, Beatriz, Minetti, Erika T., Chong, Brian S. H., Gower, Adam C., Bachschmid, Markus M., Matsui, Reiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138033/ https://www.ncbi.nlm.nih.gov/pubmed/35624731 http://dx.doi.org/10.3390/antiox11050867

Ejemplares similares

Role of Glutaredoxin-1 and Glutathionylation in Cardiovascular Diseases
por: Burns, Mannix, et al.
Publicado: (2020)

IL-33 induction and signaling are controlled by glutaredoxin-1 in mouse macrophages
por: Weinberg, Ellen O., et al.
Publicado: (2019)

Production of adeno-associated virus vectors for in vitro and in vivo applications
por: Kimura, Toyokazu, et al.
Publicado: (2019)

Neuronal Damage Induced by Perinatal Asphyxia Is Attenuated by Postinjury Glutaredoxin-2 Administration
por: Romero, Juan Ignacio, et al.
Publicado: (2017)

HLSC-Derived Extracellular Vesicles Attenuate Liver Fibrosis and Inflammation in a Murine Model of Non-alcoholic Steatohepatitis
por: Bruno, Stefania, et al.
Publicado: (2020)

Oral Supplementation of Sodium Butyrate Attenuates the Progression of Non-Alcoholic Steatohepatitis
por: Baumann, Anja, et al.
Publicado: (2020)

The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2020)

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
por: Lee, Kuei-Chuan, et al.
Publicado: (2023)

Polydatin attenuates diet-induced nonalcoholic steatohepatitis and fibrosis in mice
por: Li, Rui, et al.
Publicado: (2018)

Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis
por: Lee, Jung Il, et al.
Publicado: (2019)

P2X7 Receptor in Alcoholic Steatohepatitis and Alcoholic Liver Fibrosis
por: Xia, Guo-Qing, et al.
Publicado: (2022)

Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand
por: Phisalprapa, Pochamana, et al.
Publicado: (2021)

Metabolomic Predictors of Non-alcoholic Steatohepatitis and Advanced Fibrosis in Children
por: Kordy, Kattayoun, et al.
Publicado: (2021)

Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model
por: Morishita, Asahiro, et al.
Publicado: (2022)

Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat
por: Yoshiji, Hitoshi, et al.
Publicado: (2009)

S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis
por: Mazo, Daniel FC, et al.
Publicado: (2013)

An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis
por: Matsumoto, Masahiko, et al.
Publicado: (2013)

Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis
por: Verlinden, Wim, et al.
Publicado: (2020)

Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis
por: Angelini, Giulia, et al.
Publicado: (2023)

Exenatide Attenuates Non-Alcoholic Steatohepatitis by Inhibiting the Pyroptosis Signaling Pathway
por: Liu, Yu, et al.
Publicado: (2021)

The Influence of Different Fat Sources on Steatohepatitis and Fibrosis Development in the Western Diet Mouse Model of Non-alcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Machine learning to predict progression of non‐alcoholic fatty liver to non‐alcoholic steatohepatitis or fibrosis
por: Ghandian, Sina, et al.
Publicado: (2022)

S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis [Corrigendum]
Publicado: (2013)

A novel model of non-alcoholic steatohepatitis with fibrosis and carcinogenesis in connexin 32 dominant-negative transgenic rats
por: Naiki-Ito, Aya, et al.
Publicado: (2020)

Characterization of High-Fat, Diet-Induced, Non-alcoholic Steatohepatitis with Fibrosis in Rats
por: Xu, Zheng-Jie, et al.
Publicado: (2009)

Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease
por: Gallego-Durán, Rocío, et al.
Publicado: (2016)

Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis
por: Li, Yadi, et al.
Publicado: (2021)

Artemether Ameliorates Non-Alcoholic Steatohepatitis by Repressing Lipogenesis, Inflammation, and Fibrosis in Mice
por: Xu, Jia, et al.
Publicado: (2022)

Targeting acid ceramidase ameliorates fibrosis in mouse models of non-alcoholic steatohepatitis
por: Yu, Amy, et al.
Publicado: (2022)

IL-6 Deficiency Attenuates Murine Diet-Induced Non-Alcoholic Steatohepatitis
por: Mas, Emmanuel, et al.
Publicado: (2009)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1
por: Xi, Yue, et al.
Publicado: (2021)

Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease
por: Daher, Saleh, et al.
Publicado: (2018)

Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system
por: Kostrzewski, Tomasz, et al.
Publicado: (2021)

Systems Level Metabolic Phenotype of Methotrexate Administration in the Context of Non-alcoholic Steatohepatitis in the Rat
por: Kyriakides, Michael, et al.
Publicado: (2014)

Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis
por: Marin, Veronica, et al.
Publicado: (2017)

A novel prostaglandin I(2) agonist, ONO-1301, attenuates liver inflammation and suppresses fibrosis in non-alcoholic steatohepatitis model mice
por: Motegi, Satoko, et al.
Publicado: (2022)

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model
por: Stefano, J.T., et al.
Publicado: (2015)

Andrographolide Ameliorates Inflammation and Fibrogenesis and Attenuates Inflammasome Activation in Experimental Non-Alcoholic Steatohepatitis
por: Cabrera, Daniel, et al.
Publicado: (2017)

C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis
por: Rahman, Khalidur, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tmqqc06pdt1vcbdakfcqp5opj7